Peer-reviewedLicence not statedClinical lymphoma, myeloma & leukemia
SOHO State of the Art Updates and Next Questions | The Evolving AML Treatment Paradigm
- 1Leukemia Program, Massachusetts General Hospital, Mass General Brigham Cancer Institute, Boston, MA, 02114, USA
- 2Harvard Medical School, Boston, MA, 02115, USA
Related
- Permissive Cardiotoxicity: An Evolving Paradigm
- Maternal–Fetal Oncology Intelligence: Self-Evolving Foundation Models and Digital Twin Ecosystems for Precision Cancer Prediction, Treatment Optimization, and Maternal–Fetal Outcome Forecasting
- Rethinking the concept of disease modification in an evolving Parkinson's disease treatment landscape
- Combination of antibody–drug conjugates with immunotherapy: a new paradigm in cancer treatment
- Just-in-Time Neuromodulation: A Precision, State-Dependent Paradigm for On-Demand Brain Intervention
BibTeX
@article{olesinski2026soho,
title = {{SOHO State of the Art Updates and Next Questions | The Evolving AML Treatment Paradigm}},
author = {Elyse A. Olesinski and Brandon J. Aubrey and Amir T. Fathi},
journal = {Clinical lymphoma, myeloma \& leukemia},
year = {2026},
month = sep,
doi = {10.1016/j.clml.2026.09.016},
url = {https://doi.org/10.1016/j.clml.2026.09.016},
}
RIS
TY - JOUR
TI - SOHO State of the Art Updates and Next Questions | The Evolving AML Treatment Paradigm
AU - Elyse A. Olesinski
AU - Brandon J. Aubrey
AU - Amir T. Fathi
PY - 2026
DA - 2026/09/25
JO - Clinical lymphoma, myeloma & leukemia
DO - 10.1016/j.clml.2026.09.016
UR - https://doi.org/10.1016/j.clml.2026.09.016
SN - 2152-2650
SN - 2152-2669
ER -